Read the latest reports, briefs, and resources from I-MAK:
A Data Brief on Medicare-Negotiated Drugs: Eliquis, Ozempic, Rybelsus and Wegovy
This data brief accompanies updates to I-MAK’s Drug Patent Book database,1 which now includes nine of the drug products that formed part of the first Medicare negotiation list under the Inflation Reduction Act, as well as the products Ozempic, Rybelsus, and Wegovy (semaglutide) that have been included in the list of medications selected for the…
The Heavy Price of GLP-1 Drugs: How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies
This brief examines the financialized business model of Novo Nordisk and Eli Lilly for the leading GLP-1 products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). It shows how these companies are using the patent system as a key tool to maximize revenues, profitability, and shareholder returns. Through the creation of patent thickets,…
Biologics, Biosimilars and Patents: A Beginner’s Guide
Given the recent history of the BPCIA and the ongoing understanding of how the regulatory aspects are working in practice, including the multiple types of biologic products that are covered by the law, it can seem quite a complicated system for those not in the business. It is with this in mind that we created…
I-MAK & AELP: The Costs of Pharma Cheating
ITC Testimony
Request for Comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (USPTO Docket No. PTO-P-2022-0025)
Public Comment Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session
Supplemental Comments on the Joint USPTO-FDA Collaboration Initiatives Listening Session
Drug Patent Book
The Truth About America’s Top Selling Drugs 2021
Learn more about how you can help build a more equitable system for all